Related Experiment Videos
Statin treatment following coronary artery stenting and one-year survival
Albert Schömig1, Julinda Mehilli, Heidrun Holle
1Deutsches Herzzentrum and 1. Medizinische Klinik rechts der Isar, Technische Universität, Munich, Germany. aschoemig@dhm.mhn.de
Insights
Statin therapy after coronary artery stenting significantly improves one-year survival in patients with coronary artery disease. This treatment reduces the risk of death by approximately 50% in stenting patients.
Area of Science:
- Cardiology
- Pharmacology
- Public Health
Background:
- Coronary artery stenting is a common procedure for symptomatic coronary artery disease (CAD).
- Statin therapy is proven to improve survival in conservatively managed CAD patients.
- The benefit of statins in patients undergoing coronary stenting was previously unknown.
Purpose of the Study:
- To evaluate the impact of post-procedure statin therapy on one-year survival.
- To determine if statins offer survival benefits to patients after coronary artery stenting.
Main Methods:
- A cohort of 4,520 patients under 80 years old undergoing coronary stenting was analyzed.
- One-year mortality was compared between 3,585 patients receiving statins and 935 not receiving statins post-procedure.
Main Results:
- Patients receiving statins had a one-year mortality rate of 2.6% versus 5.6% in non-statin users.
- Statin therapy was associated with a 54% unadjusted reduction in one-year mortality (OR 0.46).
- Adjusted analysis showed a 49% reduction in mortality risk (OR 0.51) with statins, consistent across subgroups.
Conclusions:
- Statin therapy administered after coronary artery stenting improves patient survival.
- The survival benefit of statins is independent of patient characteristics at the time of intervention.
Objectives:
We assessed the influence of statin therapy given after the procedure on one-year survival of patients treated with coronary artery stenting.
Background:
Coronary artery stenting is currently a common treatment option for patients with symptomatic coronary artery disease (CAD). Although several secondary prevention trials have demonstrated improved survival achieved with statin therapy in conservatively treated patients with CAD, it is not known whether this benefit can also be expected in patients undergoing percutaneous coronary interventions with intraluminal stenting.
Methods:
This study included 4,520 patients younger than 80 years who underwent coronary artery stenting and were discharged from the hospital in the period October 1995 through September 1999. We compared one-year mortality of 3,585 patients who received statins after stenting with that of 935 patients who did not.
Results:
The mortality rate at one year was 2.6% among patients who received statins and 5.6% among those who did not. Thus, statin therapy at discharge was associated with an unadjusted odds ratio (OR) of 0.46 (95% confidence interval [CI], 0.33 to 0.65), indicating a 54% reduction in the risk of death at one year. After adjusting for other covariates, the risk reduction associated with statin therapy was 49%, OR 0.51 (95% CI, 0.36 to 0.71). This reduction was observable in most of the subgroups of patients.
Conclusions:
The results of this nonrandomized study show that statin therapy improves survival after coronary artery stenting independent of patient characteristics recorded on the day of the intervention.